Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cocrystal Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
COCP
Nasdaq
2834
https://www.cocrystalpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cocrystal Pharma Inc
COCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…
- Apr 23rd, 2024 2:10 pm
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- Mar 28th, 2024 12:00 pm
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
- Mar 19th, 2024 12:00 pm
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
- Mar 5th, 2024 1:30 pm
COCP: Cocrystal Pharma provides updates on its clinical programs.
- Feb 20th, 2024 1:40 pm
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
- Jan 4th, 2024 1:00 pm
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
- Dec 6th, 2023 1:00 pm
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
- Nov 29th, 2023 1:00 pm
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
- Nov 27th, 2023 1:00 pm
COCP: Cocrystal Pharma reports 3rd quarter financial results and provides updates on clinical trials.
- Nov 14th, 2023 4:24 pm
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
- Nov 13th, 2023 1:00 pm
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
- Nov 9th, 2023 1:00 pm
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
- Oct 31st, 2023 12:00 pm
COCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial.
- Oct 2nd, 2023 4:14 pm
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
- Sep 28th, 2023 12:00 pm
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
- Sep 5th, 2023 12:00 pm
COCP: Cocrystal Pharma reports 2nd quarter 2023 financial results and provides updates on drug pipeline.
- Aug 16th, 2023 1:11 pm
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
- Aug 14th, 2023 12:00 pm
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
- Aug 8th, 2023 12:00 pm
Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
- May 31st, 2023 12:00 pm
Scroll